Tag #Lilly

What is the immediate impact of CVS Health's decision to remove Zepbound from its preferred formulary on patient access and affordability?

CVS Health will remove Eli Lilly's weight-loss drug, Zepbound, from its preferred formulary starting July 1, 2025, prioritizing Novo Nordisk's Wegovy instead. This impacts 90 million CVS Caremark members, potentially limiting Zepbound access or increasing out-of-pocket costs for many. Lilly is mitigating this by offering Zepbound through its own direct-to-consumer pharmacy and telehealth partnerships, bypassing traditional gatekeepers.